Responsiveness of Migraine‐ACT and MIDAS Questionnaires for Assessing Migraine Therapy

García, M; Vicente, Baos; Láinez, Miguel J. A.; Pascual, Julio; López‐Gil, Arturo

doi:10.1111/j.1526-4610.2007.01026.x

Cited by 16 publications

(14 citation statements)

References 30 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Migraine is a debilitating disorder, and proper use of acute medication has been demonstrated to reduce disability over time. 18 Several studies suggested that adequate acute treatment is associated with improved outcomes, [19][20][21][22] and inadequate treatment has been recognized as an important barrier to optimal health outcomes. 23,24 Although triptans are safe in appropriately selected patients, perceptions about safety influence the behavior of both doctors and patients.…”

Section: Discussionmentioning

confidence: 99%

Triptan Use as a Function of Cardiovascular Risk. A Population‐Based Study

et al. 2010

View full text Add to dashboard Cite

Triptan use is lower in those with vs without CV risk, suggesting that doctors and/or patients fear using triptans in individuals at risk to CVD. Furthermore, triptan use in those with established CVD increases with headache-related disability, suggesting that patients and providers balance risks and benefits. Additional and analytical data are needed on the safety of triptans in the setting of CVD risk. This study has not assessed adequacy of care.

show abstract

Section: Discussionmentioning

confidence: 99%

Triptan Use as a Function of Cardiovascular Risk. A Population‐Based Study

et al. 2010

View full text Add to dashboard Cite

show abstract

“…We believe this reflects a substantial rate of underuse for a class of treatments that are widely recognized as effective. As several studies have demonstrated that use of adequate acute therapies is associated with improved outcomes, 23‐26 undertreatment is a barrier to good outcomes.…”

Section: Discussionmentioning

confidence: 99%

Rates and Predictors of Starting a Triptan: Results From the American Migraine Prevalence and Prevention Study

Bigal¹,

Buse²,

Chen

et al. 2010

Headache

View full text Add to dashboard Cite

show abstract

“…The MIDAS has been used as an outcome measure in both observational studies and clinical trials. The MIDAS is sensitive to change over time . Controlled trials show that the MIDAS is sensitive to treatment effects in both episodic and chronic migraine …”

Section: Methodsmentioning

confidence: 99%

Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache‐Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study

Buse

Serrano

Reed³

et al. 2015

Headache

View full text Add to dashboard Cite

Background.-Though triptans are the most widely used acute treatments for migraine, response to treatment is sometimes suboptimal. Triptan therapy is often augmented by the addition of other acute treatments. The benefits of this practice have not been examined in large-scale, real-world observational studies.Objectives.-To assess changes in headache-related disability associated with adding additional acute treatments to a triptan regimen by category of added treatment including: a second triptan, nonsteroidal anti-inflammatory drugs (NSAID), opioids or barbiturates.Methods.-Subjects were participants in the American Migraine Prevalence and Prevention study, a longitudinal, US population-based study of individuals with "severe" headache. Respondents who met International Classification of Headache Disorders 3 beta criteria for migraine were on triptan therapy per respondent self-report, used the same triptan, and provided headache-related disability data for at least 2 consecutive years. Subjects were divided based on headache days per month into 3 groups: low-frequency episodic migraine (LFEM, 0-4), moderate-frequency episodic migraine (MFEM, 5-9), and high-frequency episodic migraine/chronic migraine (HFEM/CM, ≥ 10 headache days per month). HFEM and CM were combined into a single group for analyses because of sample size limitations. Patterns of acute treatment for migraine were monitored from one year to the next over the following couplets of years ( Conclusions.-While the effects of adding vs staying consistent on the outcome of headache-related disability varied by medication type added and headache frequency strata, in general, these results suggest that for individuals with migraine, adding acute therapies to current triptan use is generally not associated with reductions in headache-related disability. The results were strongest among persons with HFEM and CM. These results identify important unmet medical needs in current migraine management, especially among patients with high-frequency migraine, and suggest that alternative treatment strategies are needed to improve patient outcomes.

show abstract

Responsiveness of Migraine‐ACT and MIDAS Questionnaires for Assessing Migraine Therapy

Abstract: These results suggest that the Migraine-ACT questionnaire can be used more reliably than the MIDAS questionnaire for detecting improvements in treatment of new and follow-up patients with migraine.

Cited by 16 publications

References 30 publications

Triptan Use as a Function of Cardiovascular Risk. A Population‐Based Study

Triptan Use as a Function of Cardiovascular Risk. A Population‐Based Study

Rates and Predictors of Starting a Triptan: Results From the American Migraine Prevalence and Prevention Study

Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache‐Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study

Contact Info

Product

Resources

About